Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus the PD-L1 Antibody Durvalumab Followed by Surgery or Definitive Chemoradiation Boost and Consolidation Durvalumab in Resectable Stage III NSCLC.

NCT04202809 is registered in ClinicalTrials.gov with University Hospital, Essen as lead sponsor.

NCT NCT04202809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04202809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus the PD-L1 Antibody Durvalumab Followed by Surgery or Definitive Chemoradiation Boost and Consolidation Durvalumab in Resectable Stage III NSCLC.
Lead sponsor
University Hospital, Essen
Phase
Phase 2
Overall status
Unknown status
Start date
January 13, 2020
Completion date
April 30, 2025
Enrollment
90 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage iii